AdhexPharma ranked 59th among France’s long-term growth champions by Les Echos Week-End and Statista

We are thrilled to announce that AdhexPharma has achieved a remarkable milestone by being ranked 59th among France’s long-term growth champions (2014–2024) by Les Echos Week-End and Statista. This prestigious list celebrates the 100 French companies that have demonstrated exceptional and consistent growth over the past decade, recognizing both performance and long-term resilience.

Over the 2014–2024 period, AdhexPharma achieved an average annual growth rate of 27.12%, representing an overall growth of 1,002.17%. Our workforce has grown from 34 employees in 2014 to 151 in 2024, with 90 additional positions planned at the end of 2026, illustrating our focus on sustainable growth and investment in our teams.

About the 2014–2024 Long-Term Growth Champions by Les Echos Week-End and Statista 

To celebrate the 10th anniversary of the Growth Champions rankings, Les Echos Week-End and Statista have highlighted the 100 French companies that have achieved the strongest growth over a full decade. This ranking recognizes businesses that have not only delivered outstanding financial performance but have also maintained stability and resilience in the face of economic and geopolitical challenges.

Being featured in this ranking is a testament to an organization’s ability to innovate, adapt, and lead in its sector.

Oral films and transdermal patches, the future of medication? 

In an era where convenience and efficiency are paramount, oral films and transdermal patches represent the future of medication. These innovative delivery systems offer solutions that align with modern healthcare needs, addressing the growing demand for more accessible and user-friendly treatment options.

These advanced delivery systems provide numerous advantages over traditional methods, including improved patient compliance, precise dosing and reduced side effects, which are crucial in enhancing the overall effectiveness of medical treatments.

• Oral films: These dissolve quickly in the mouth, eliminating the need for water and making them ideal for patients suffering from dysphagia, such as the elderly or those with certain medical conditions. This ease of administration not only improves the patient experience but also ensures that medication is taken as prescribed, thereby increasing its efficacy.
• Transdermal patches: These provide a steady release of medication through the skin, maintaining consistent therapeutic levels and reducing the risk of gastrointestinal complications associated with oral medications. They are particularly beneficial for patients who require long-term medication management, as it reduces the frequency of dosing and enhances adherence to treatment regimens.

As the pharmaceutical industry continues to evolve, these technologies are poised to revolutionize how we administer and experience medication, paving the way for more personalized and patient-friendly treatment options that cater to the diverse needs of patients across the globe. By integrating these innovative delivery systems into mainstream healthcare, we can anticipate a future where medication is not only more effective but also more aligned with the lifestyles and preferences of patients, ultimately leading to better health outcomes and improved quality of life.

Building momentum for the future

While this accomplishment marks a significant milestone in our journey, it also serves as a catalyst that fuels our drive to continue striving for excellence in every aspect of our operations. This recognition not only validates our past efforts but also inspires us to push the boundaries of innovation and quality in the pharmaceutical industry. Our dedication to excellence drives us to explore and develop cutting-edge solutions and set new standards in the industry, ensuring that we remain at the forefront of pharmaceutical advancements.

Since its founding in 2008, AdhexPharma has steadily built a reputation for quality and innovation. We currently manufacture nine approved products, including oral films and transdermal patches, with an annual output of more than 200 million units per year. Our 27% annual growth rate over the past decade reflects our commitment to meeting the evolving needs of the healthcare sector.

To support this ongoing expansion and to accommodate future projects, we are excited to announce the construction of a new state-of-the-art 8,000 m² facility, set for completion in just a few weeks, marking the next step in our growth journey. This new hub of pharmaceutical excellence in France will feature advanced production units, expansive storage facilities, cutting-edge quality control laboratories, and modern administrative offices.

This strategic development will not only ensure our continued compliance with regulatory standards but also position us to welcome new projects and innovations, further solidifying our role as a leader in the pharmaceutical industry.